Amplification of relevant genes, including AKT1, Kirsten rat sarcoma (KRAS), and proto-oncogene tyrosine-protein kinase Yes (YES1), were detected (data not shown) but were not enriched in the osimertinib-resistant xenograft tumor, osimertinib-3. This evidence concerns the gene AKT1 and neoplasm.